Evaluation of Long-term Buprenorphine Plasma Exposure in Subjects Who Received at Least 2 Subcutaneous (SC) Injections of Extended-release Buprenorphine (SUBLOCADE) in Phase III Studies
Phase of Trial: Phase IV
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs Buprenorphine (Primary)
- Indications Opioid abuse
- Focus Pharmacokinetics
- Sponsors Indivior
- 24 Jul 2019 Status changed from recruiting to completed.
- 20 Feb 2019 Status changed from not yet recruiting to recruiting.
- 07 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Feb 2019.